{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:26:19Z","timestamp":1790889979240,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2023B110009"],"award-info":[{"award-number":["2023B110009"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270321"],"award-info":[{"award-number":["82270321"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018555","name":"Science and Technology Program of Guizhou Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Department of Science and Technology of Guangdong Province","doi-asserted-by":"publisher","award":["2019B020230004"],"award-info":[{"award-number":["2019B020230004"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejphar.2026.178520","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:03:02Z","timestamp":1767859382000},"page":"178520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Empagliflozin protects against doxorubicin-induced arrhythmia by AMPK\/mTOR-mediated autophagy in cardiomyocyte"],"prefix":"10.1016","volume":"1014","author":[{"given":"Hui-yi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-dong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-qun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-yu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-mei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178520_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113677","article-title":"Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats","volume":"170","author":"Arag\u00f3n-Herrera","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178520_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2017.01.007","article-title":"Autophagic dysregulation in doxorubicin cardiomyopathy","volume":"104","author":"Bartlett","year":"2017","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178520_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1385\/CT:3:4:319","article-title":"Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity","volume":"3","author":"Boucek","year":"2003","journal-title":"Cardiovasc. Toxicol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13010094","article-title":"Apelinergic system affects electrocardiographic abnormalities induced by doxorubicin","volume":"13","author":"Buczma","year":"2025","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.ejphar.2026.178520_bib5","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.18632\/oncotarget.13596","article-title":"Astragalus polysaccharide restores autophagic flux and improves cardiomyocyte function in doxorubicin-induced cardiotoxicity","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178520_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s002469900355","article-title":"Effects of doxorubicin on diastolic function, contractile reserve, and ventricular-vascular coupling in piglets","volume":"19","author":"Cassidy","year":"1998","journal-title":"Pediatr. Cardiol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.anes.0000267536.72735.6d","article-title":"Electrophysiologic mechanism underlying action potential prolongation by sevoflurane in rat ventricular myocytes","volume":"107","author":"Chae","year":"2007","journal-title":"Anesthesiology"},{"issue":"7","key":"10.1016\/j.ejphar.2026.178520_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJMra1205406","article-title":"Autophagy in human health and disease","volume":"368","author":"Choi","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178520_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1476-5381.2009.00371.x","article-title":"Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks)","volume":"159","author":"Ducroq","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178520_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/jmcc.1994.1019","article-title":"Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit","volume":"26","author":"Earm","year":"1994","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178520_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12070635","article-title":"Exercise augments the effect of SGLT2 inhibitor dapagliflozin on experimentally induced diabetic cardiomyopathy, possible underlying mechanisms","volume":"12","author":"Eldesoqui","year":"2022","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.ejphar.2026.178520_bib13","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ejphar.2026.178520_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042201","article-title":"Investigation of the antiremodeling effects of losartan, mirabegron and their combination on the development of doxorubicin-induced chronic cardiotoxicity in a rat model","volume":"23","author":"Freiwan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178520_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-019-0036-7","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardio-Oncology"},{"issue":"12","key":"10.1016\/j.ejphar.2026.178520_bib16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/europace\/eup300","article-title":"Introducing a new entity: chemotherapy-induced arrhythmia","volume":"11","author":"Guglin","year":"2009","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178520_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178520_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235640","article-title":"Fluid overload is a determinant for cardiac structural and functional impairments in type 2 diabetes mellitus and chronic kidney disease stage 5 not undergoing dialysis","volume":"15","author":"Han","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178520_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-025-00401-z","article-title":"ACEi and ARBs as primary prevention of cancer therapy-related cardiomyopathy in patients undergoing chemotherapy with anthracyclines: a systematic review and meta-analysis","volume":"14","author":"Harmouch","year":"2025","journal-title":"Cardiol. Ther."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178520_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11886-017-0846-x","article-title":"Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions","volume":"19","author":"Jain","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"issue":"16","key":"10.1016\/j.ejphar.2026.178520_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25163606","article-title":"Effects of secretome from fat tissues on ion currents of cardiomyocyte modulated by sodium-glucose transporter 2 inhibitor","volume":"25","author":"Jhuo","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.ejphar.2026.178520_bib22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/cvr\/cvs282","article-title":"Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes","volume":"96","author":"Kawaguchi","year":"2012","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178520_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"2\u20133","key":"10.1016\/j.ejphar.2026.178520_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejphar.2010.05.038","article-title":"Heart rate correction of the QT duration in rats","volume":"641","author":"Kmecova","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178520_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114674","article-title":"Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts","volume":"192","author":"Lee","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178520_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20071680","article-title":"Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-induced diabetic rats","volume":"20","author":"Lee","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"17","key":"10.1016\/j.ejphar.2026.178520_bib28","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American heart association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2026.178520_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105668","article-title":"Sodium glucose co-transporter 2 inhibitor prevents nephrolithiasis in non-diabetes by restoring impaired autophagic flux","volume":"114","author":"Liu","year":"2025","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.ejphar.2026.178520_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/auto.18658","article-title":"Enhancing lysosome biogenesis attenuates BNIP3-induced cardiomyocyte death","volume":"8","author":"Ma","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.ejphar.2026.178520_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116650","article-title":"Cardiovascular outcomes and molecular targets for the cardiac effects of sodium-glucose cotransporter 2 inhibitors: a systematic review","volume":"175","author":"Madonna","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178520_bib32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/cvr\/cvad009","article-title":"Empagliflozin inhibits excessive autophagy through the AMPK\/GSK3\u03b2 signalling pathway in diabetic cardiomyopathy","volume":"119","author":"Madonna","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2026.178520_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117278","article-title":"Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway","volume":"178","author":"Mattii","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.ejphar.2026.178520_bib34","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1093\/ndt\/gfae106","article-title":"The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis","volume":"39","author":"McEwan","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"issue":"21","key":"10.1016\/j.ejphar.2026.178520_bib35","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178520_bib36","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined","volume":"2","author":"Meraz-Mu\u00f1oz","year":"2021","journal-title":"Kidney360"},{"issue":"12","key":"10.1016\/j.ejphar.2026.178520_bib37","article-title":"Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts","volume":"6","author":"Mizuno","year":"2018","journal-title":"Phys. Rep."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178520_bib38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCIMAGING.108.838367","article-title":"Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo","volume":"2","author":"Moreo","year":"2009","journal-title":"Circ. Cardiovasc. Imag."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178520_bib39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.amjcard.2012.11.022","article-title":"Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy","volume":"111","author":"Neilan","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(197307)32:1<1::AID-CNCR2820320101>3.0.CO;2-X","article-title":"Phase II evaluation of adriamycin in human neoplasia","volume":"32","author":"O'Bryan","year":"1973","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejphar.2026.178520_bib41","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4070\/kcj.2019.0180","article-title":"Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure","volume":"49","author":"Oh","year":"2019","journal-title":"Korean Circ. J."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2006.05.005","article-title":"Adriamycin-induced myocardial toxicity: new solutions for an old problem?","volume":"117","author":"Outomuro","year":"2007","journal-title":"Int. J. Cardiol."},{"issue":"18","key":"10.1016\/j.ejphar.2026.178520_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2026.178520_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.664181","article-title":"Sodium-glucose CoTransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy","volume":"12","author":"Ren","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178520_bib45","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/europace\/eum033","article-title":"Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator","volume":"9","author":"Rudzinski","year":"2007","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-020-01040-5","article-title":"Empagliflozin prevents doxorubicin-induced myocardial dysfunction","volume":"19","author":"Sabatino","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.3922","article-title":"SGLT2 inhibitors and AMPK: the road to cellular housekeeping?","volume":"42","author":"Safaie","year":"2024","journal-title":"Cell Biochem. Funct."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178520_bib48","doi-asserted-by":"crossref","first-page":"457","DOI":"10.14740\/jocmr3011w","article-title":"Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors","volume":"9","author":"Sano","year":"2017","journal-title":"J. Clin. Med. Res."},{"issue":"11","key":"10.1016\/j.ejphar.2026.178520_bib49","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMc1600827","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Sarafidis","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ejphar.2026.178520_bib50","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","article-title":"Anthracyclines and heart failure","volume":"368","author":"Sawyer","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178520_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","article-title":"Cardiotoxicity of cytotoxic drugs","volume":"30","author":"Schimmel","year":"2004","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bcp.2012.10.005","article-title":"Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity","volume":"85","author":"Sishi","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178520_bib53","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib54","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.106.101832","article-title":"Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction","volume":"318","author":"Song","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178520_bib55","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V","article-title":"Acute arrhythmogenicity of doxorubicin administration","volume":"60","author":"Steinberg","year":"1987","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejphar.2026.178520_bib56","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ndt\/gfab048","article-title":"Efficacy and safety of combination therapy with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"37","author":"Tian","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178520_bib57","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00005344-200009000-00012","article-title":"Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry","volume":"36","author":"Tokudome","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejphar.2026.178520_bib58","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/dc18-0588","article-title":"SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management","volume":"41","author":"van Baar","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.178520_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115686","article-title":"Empagliflozin treatment of cardiotoxicity: a comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications","volume":"168","author":"Vaziri","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178520_bib60","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178520_bib61","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr. Cardiol. Rev."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178520_bib62","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00018-020-03729-y","article-title":"Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways","volume":"78","author":"Wang","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"11","key":"10.1016\/j.ejphar.2026.178520_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/biology9110369","article-title":"TLR9 binding to beclin 1 and mitochondrial SIRT3 by a sodium-glucose Co-Transporter 2 inhibitor protects the heart from doxorubicin toxicity","volume":"9","author":"Wang","year":"2020","journal-title":"Biology"},{"issue":"3","key":"10.1016\/j.ejphar.2026.178520_bib64","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bcp.2014.01.040","article-title":"Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK","volume":"88","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178520_bib65","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/01.RES.76.4.645","article-title":"Effects of doxorubicin on excitation-contraction coupling in Guinea pig ventricular myocardium","volume":"76","author":"Wang","year":"1995","journal-title":"Circ. Res."},{"issue":"15","key":"10.1016\/j.ejphar.2026.178520_bib66","article-title":"Differential cardiotoxic electrocardiographic response to doxorubicin treatment in conscious versus anesthetized mice","volume":"9","author":"Warhol","year":"2021","journal-title":"Phys. Rep."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178520_bib67","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/1097-0142(197911)44:5<1588::AID-CNCR2820440508>3.0.CO;2-X","article-title":"Sudden death during doxorubicin administration","volume":"44","author":"Wortman","year":"1979","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178520_bib68","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1124\/jpet.111.189589","article-title":"Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy","volume":"341","author":"Xu","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2026.178520_bib69","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.biopha.2018.10.095","article-title":"Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat","volume":"109","author":"Yang","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"10254","key":"10.1016\/j.ejphar.2026.178520_bib70","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejphar.2026.178520_bib71","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1172\/JCI27523","article-title":"Cardiac autophagy is a maladaptive response to hemodynamic stress","volume":"117","author":"Zhu","year":"2007","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.ejphar.2026.178520_bib72","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ejphar.2026.178520_bib73","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/aps.2011.96","article-title":"Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure","volume":"32","author":"Zong","year":"2011","journal-title":"Acta Pharmacol. Sin."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:59:05Z","timestamp":1769115545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":73,"alternative-id":["S0014299926000026"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178520","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin protects against doxorubicin-induced arrhythmia by AMPK\/mTOR-mediated autophagy in cardiomyocyte","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178520"}}